1. Generics Bulletin
  2. >>Business
  3. >>Deals

Similis Bio And Blau To Co-Develop Four Biosimilars For The Americas

The Drugs Have An Estimated Global Market Value Of $42bn

 
• By Rosalind Rei

JSR Life Science’s new business unit embarks on its first partnership with publicly listed Brazilian pharmaceutical.

Glassy Globe, Showing The Americas, Set Against A Pale Gradient Background
The biosimilars will initially launch in North and South America • Source: Shutterstock

Similis Bio has signed its first development and license agreement with Brazilian pharmaceutical firm Blau Farmaceutica.

Over the next several years, the partnership will develop four biosimilar assets

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.